Literature DB >> 22525142

Prostate cancer: Bone Scan Index made easy, at last.

Bertrand Tombal.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22525142     DOI： 10.1038/nrurol.2012.79

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

Authors:  David Ulmert; Reza Kaboteh; Josef J Fox; Caroline Savage; Michael J Evans; Hans Lilja; Per-Anders Abrahamsson; Thomas Björk; Axel Gerdtsson; Anders Bjartell; Peter Gjertsson; Peter Höglund; Milan Lomsky; Mattias Ohlsson; Jens Richter; May Sadik; Michael J Morris; Howard I Scher; Karl Sjöstrand; Alice Yu; Madis Suurküla; Lars Edenbrandt; Steven M Larson
Journal:  Eur Urol       Date:  2012-01-27       Impact factor: 20.096

3.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

4.  Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.

Authors:  Elizabeth R Dennis; Xiaoyu Jia; Irina S Mezheritskiy; Ryan D Stephenson; Heiko Schoder; Josef J Fox; Glenn Heller; Howard I Scher; Steven M Larson; Michael J Morris
Journal:  J Clin Oncol       Date:  2012-01-09       Impact factor: 44.544

5.  Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer.

Authors:  R Venkitaraman; G J R Cook; D P Dearnaley; C C Parker; V Khoo; R Eeles; R A Huddart; A Horwich; S A Sohaib
Journal:  J Med Imaging Radiat Oncol       Date:  2009-06       Impact factor: 1.735

Review 6.  Assessment of therapeutic response in patients with metastatic bone disease.

Authors:  Andrew Clamp; Sarah Danson; Huy Nguyen; David Cole; Mark Clemons
Journal:  Lancet Oncol       Date:  2004-10       Impact factor: 41.316

7.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

8.  A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.

Authors:  M Imbriaco; S M Larson; H W Yeung; O R Mawlawi; Y Erdi; E S Venkatraman; H I Scher
Journal:  Clin Cancer Res       Date:  1998-07       Impact factor: 12.531

9.  Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?

Authors:  Bertrand Tombal; Frederic Lecouvet
Journal:  Adv Urol       Date:  2011-10-16

Review 10.  Imaging metastatic bone disease from carcinoma of the prostate.

Authors:  C Messiou; G Cook; N M deSouza
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.